An Open-label Proof of Concept Study to Assess the Efficacy, Safety and Pharmacokinetics of LFG316, an Anti-C5 Monoclonal Antibody in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Phase of Trial: Phase II
Latest Information Update: 13 Mar 2018
At a glance
- Drugs Tesidolumab (Primary)
- Indications Paroxysmal nocturnal haemoglobinuria
- Focus Proof of concept; Therapeutic Use
- Sponsors Novartis; Novartis Pharmaceuticals
- 24 Jan 2018 Planned End Date changed from 20 Dec 2023 to 1 Nov 2022.
- 24 Jan 2018 Planned primary completion date changed from 20 Dec 2023 to 1 Nov 2022.
- 01 Jun 2017 Planned End Date changed from 19 Dec 2023 to 20 Dec 2023.